Recombinant Rat Tie-2 Fc Chimera Protein, CF

Catalog #: 3874-T2 Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
3874-T2-100

R&D Systems Recombinant Proteins and Enzymes

1 Image

Product Details

Supplemental Products

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Rat Tie-2 Fc Chimera Protein, CF Summary

Product Specifications

Purity

>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.01 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its binding ability in a functional ELISA. Immobilized rrTie-2/Fc Chimera at 4 µg/mL (100 µL/well) can bind rhAngiopoietin-2 with a linear range of 0.8-50 ng/mL.

Source

Mouse myeloma cell line, NS0-derived rat Tie-2 protein

Rat Tie-2 (Ala23-Leu743) Accession # NP_001099207	IEGRMD	Human IgG₁ (Pro100-Lys330)
N-terminus		C-terminus

Accession #

NP_001099207

N-terminal Sequence
Analysis

Ala23

Structure / Form

Disulfide-linked homodimer

Predicted Molecular Mass

107.3 kDa (monomer)

SDS-PAGE

120-140 kDa, reducing conditions

Product Datasheets

3874-T2

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

3874-T2

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution	Reconstitute at 100 μg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Reconstitution Calculator

Background: Tie-2

Tie-2, also known as Tek, is a 145 kDa, type I transmembrane glycoprotein receptor tyrosine kinase that is a receptor for angiopoietins (1). The 1120 amino acid (aa) rat Tie-2 precursor contains an 18 aa signal sequence, a 723 aa extracellular domain (ECD), a 25 aa transmembrane segment, and a 354 aa cytoplasmic tail (2). The ECD contains two C2 Ig-like domains, three EGF-like motifs, and three fibronectin type III repeats. The cytoplasmic region has a split tyrosine kinase domain and presumably autophosphorylates as a ligand-induced homodimer (3). Rat Tie-2 ECD shares 96%, 90% and 89% aa identity with mouse, human and bovine Tie-2, respectively, and 47% aa identity with rat Tie-1 ECD. Cells known to express Tie-2 include embryonic and adult endothelial cells, hematopoietic stem cells and a circulating population of proangiogenic Tie-2 expressing monocytes (TEM) (4 - 7). A soluble form of Tie-2, most likely the result of proteolytic cleavage, is found in serum (8). The four angiopoietins are ligands of Tie-2. Ang-1 and Ang-4 are Tie-2 activators, while Ang-2 and Ang-3 can be activators or inhibitors, depending on context (1, 9). Tie-2 is said to be important for maintaining vascular integrity. It mediates endothelial cell-smooth muscle cell communication, and inhibits endothelial cell apoptosis, thus maintaining endothelial cell survival (10 - 12). It is also absolutely required for embryonic development of the endocardium (3, 10, 13). While not essential for embryonic hematopoiesis, Ang-1 production by osteoblasts promotes quiescence ofTie-2-expressing bone marrow stem cells. This quiescence is critical for maintaining an ongoing hematopoietic capability (12, 14, 15).

References

Eklund, L and B. R. Olsen (2006) Exp. Cell Res. 312:630.
Maisonpierre, P.C. et al. (1993) Oncogene 8:1631.
Vikkula, M. et al. (1996) Cell 87:1181.
Asahara, T. et al. (1997) Science 275:964.
Dallabrida, S.M. et al. (2003) Biochem. Biophys. Res. Commun. 311:563.
Takakura, N. et al. (1998) Immunity 9:677.
DePalma, M. et al. (2005) Cancer Cell 8:211-226.
Reusch, P. et al. (2001) Angiogenesis 4:123.
Lee, H.J. et al. (2004) FASEB J. 18:1200.
Jones, N. et al. (2001) EMBO Rep. 2:438.
Wong, A. L. et al. (1997) Circ. Res. 81:567.
Hamaguchi, I. et al. (2006) Blood 107:1207.
Puri, M.C. et al. (1999) Development 126:4569.
Puri, M.C. and A. Bernstein (2003) Proc. Natl. Acad. Sci. USA 100:12753.
Arai, F. et al. (2004) Cell 118:149.

Long Name

Tyrosine Kinase with Immunoglobulin and Epidermal Growth Factor Homology Domains 2

Entrez Gene IDs

7010 (Human); 21687 (Mouse); 89804 (Rat); 396729 (Porcine); 403714 (Canine); 102122204 (Cynomolgus Monkey); 30747 (Zebrafish)

Alternate Names

angiopoietin-1 receptor; CD202b antigen; CD202b; EC 2.7.10; EC 2.7.10.1; hTIE2; p140 TEK; soluble TIE2 variant 1; soluble TIE2 variant 2; TEK tyrosine kinase, endothelial; TEK; Tie2; Tie-2; TIE2CD202b; Tunica interna endothelial cell kinase; Tyrosine-protein kinase receptor TEK; Tyrosine-protein kinase receptor TIE-2; venous malformations, multiple cutaneous and mucosal; VMCM; VMCM1